BRAF and melanoma: Combined treatment with the BRAFi dabrafenib and the MEKi trametinib in patients with BRAF V600E positive melanoma showed a 76% rate of complete or partial response with combination therapy, compared to 54% observed with dabrafenib monotherapy and improved the OS and progression-free survival (PFS) of patients with unresectable metastatic melanoma compared with vemurafenib/dabrafenib monotherapy.